Repository of Research and Investigative Information

Repository of Research and Investigative Information

Dezful University of Medical Sciences

Therapeutic effects of mesenchymal stem cells on cutaneous leishmaniasis lesions caused by Leishmania major

(2020) Therapeutic effects of mesenchymal stem cells on cutaneous leishmaniasis lesions caused by Leishmania major. Journal of global antimicrobial resistance. pp. 243-250. ISSN 2213-7173 (Electronic) 2213-7165 (Linking)

[img] Text
Therapeutic effects of mesenchymal stem cells on cutaneous leishmaniasis lesions caused by Leishmania major _ Elsevier Enhanced Reader.html

Download (572kB)

Official URL: https://www.ncbi.nlm.nih.gov/pubmed/32977079

Abstract

OBJECTIVES: Leishmania major (L. major) is a cutaneous leishmaniasis causative agent. Current chemotherapeutic methods are not totally effective in treatment of this disease. The immunomodulation and tissue repairing capability of mesenchymal stem cells (MSCs), ease of isolation, detection and in vitro culture, have encouraged biologists to use MSCs for cell therapy in different infections such as cutaneous leishmaniasis. METHODS: BALB/c mice (6-8 weeks old) were infected with L. major then divided into four groups and treated with MSCs, Glucantime, Glucantime + MSCs, or PBS. Regression of lesions, potency of macrophages for phagocytosis, proliferation of immune cells against Leishmania soluble antigen, reduction of spleen parasite burden and healing of the lesions were evaluated on days 10, 20 and 30 of treatment. RESULTS: The results indicated that the mice intralesionally injected with MSCs showed significant regression in the lesions produced by L. major by day 30. Proliferation of splenocytes stimulated with SLA (soluble leishmania antigen) in vitro in MSC-treated mice on day 20 was significantly higher than in the other groups. The potency of phagocytosis in macrophages of mice treated with MSCs was significantly higher by day 30 and healing of the lesions in this group of mice showed more progress on histopathological examinations. Spleen parasite burden showed significant reduction in the mice treated with Glucantime + MSCs by day 30. CONCLUSIONS: The results showed that including MSCs in treatment of cutaneous leishmaniasis caused by L. major is a promising approach.

Item Type: Article
Keywords: BALB/c Cutaneous leishmaniasis Mesenchymal stem cells Mice
Subjects: QS Human Anatomy > QS504-532 Histology
QU Biochemistry. Cell Biology and Genetics > QU 300-560 Cell Biology and Genetics
Divisions: Education Vice-Chancellor Department > Faculty of Medicine > Department of Basic Science > Department of Histology and Anatomy
Page Range: pp. 243-250
Journal or Publication Title: Journal of global antimicrobial resistance
Journal Index: Pubmed
Volume: 23
Identification Number: https://doi.org/10.1016/j.jgar.2020.09.005
ISSN: 2213-7173 (Electronic) 2213-7165 (Linking)
Depositing User: مهندس مهدی شریفی
URI: http://eprints.dums.ac.ir/id/eprint/726

Actions (login required)

View Item View Item